Breast cancer battleground drug not a game-changer when given for a year

+News
NEWS

Breast cancer battleground drug not a game-changer when given for a year

NZD

New Zealand Doctor

woman with cancer iStock
A small proportion of patients do better with the longer course of Herceptin, but there are disadvantages
US oncologists are reporting a trial of the breast cancer drug trastuzumab (Herceptin) has failed to demonstrate one year is significantly better than